Biotech | November 26, 2024
FDA approves BridgeBio’s Attruby for ATTR-CM treatment
Attruby is the first and only approved product with a label specifying near-complete stabilization of TTR
Attruby is the first and only approved product with a label specifying near-complete stabilization of TTR
Strengthening focus in Alzheimer's disease and neuroscience pipeline
Financing includes new funding from leading global organizations Eli Lilly and Company and EDBI
Jubilant's Radiopharma Business to expand positron emission tomography radiopharmacy network
This marks the first FDA approval of an AI-based brain disorder analysis solution from Korea
US FDA approval based on NEURO-TTRansform Phase III results
The positive safety review from the DSMB enables the trial to move forward as planned, with an estimated completion date in December 2023
ZYIL1 is a novel oral small molecule NLRP3 inhibitor which has demonstrated CSF penetration in non-human primates
Charsire Biotechnology Corp. has successfully developed a revolutionary new drug (BAC) for Alzheimer's disease
According to the National Institutes of Health, more than six million Americans, most age 65 or older, may have dementia caused by Alzheimer's disease, a brain disorder known to slowly destroy memory and thinking skills
Subscribe To Our Newsletter & Stay Updated
